Abstract:Objective: To study the clinicopathological features, immunohistochemical phenotypes, molecular changes, differential diagnosis and prognosis of isolated intraductal carcinoma of the prostate (iIDC-P). Methods: Three iIDC-P cases were collected retrospectively from 2016 to 2022 at Ningbo Clinical Pathology Diagnosis Center, Ningbo, China. The clinicopathologic features and immunophenotypic profiles were studied using light microscopy and immunohistochemistry. A targeted next-generation sequencing panel was used to analyze cancer-associated mutations. Follow-up and literature review were also performed. Results: The patients' ages were 61, 67 and 77 years, and their preoperative prostate specific antigen (PSA) levels were 7.99, 7.99 and 4.86 μg/L, respectively. Case 1 and 2 were diagnosed on needle biopsy and radical prostatectomy (RP) specimens, and case 3 was diagnosed on a specimen of transurethral resection of the prostate (TURP). The RP specimen was entirely submitted for histologic examination. In the case 1, iIDC-P was found in one tissue core (involving two ducts) in the biopsy specimen, and in 6 sections (diameter, 0.3-1.1 cm) from the radical prostatectomy specimen, and one section had separate foci of low-grade acinar adenocarcinoma (diameter, 0.05 cm). In the case 2, 6 tissue sections from the biopsy specimens showed iIDC-P, and 13 sections from RP specimen showed iIDC-P (diameter, 0.5-1.6 cm), and the other 3 sections had separate low grade acinar adenocarcinoma (diameter, 0.6 cm). In the case 3, 5 tissue blocks from the TURP specimen showed iIDC-P. The case 1 and 2 showed solid architecture with expansile proliferation of neoplastic cells in native ducts and acini. The case 3 showed dense or loose cribriform pattern, with marked cytological atypia, and frequent mitotic figures. Comedonecrosis was found in solid or dense cribriform glands in the case 2. Immunohistochemically, surrounding basal cells were highlighted using high-molecular-weight cytokeratin (34βE12 and CK5/6) and p63, while P504s was positive in the tumor cells. The tumor cells were also positive for AR and prostate markers (NKX3.1, PSA and PSAP), and negative for GATA3. The iIDC-P and acinar adenocarcinoma both showed weak PTEN expression and no ERG (nuclear) expression. In case 2 and 3, targeted sequencing revealed activated oncogenic driver mutations in MAPK and PI3K pathway genes (KRAS, MTOR and PTEN). In addition, pathogenic mutation in TP53 and FOXA1 mutation were found in the case 2 and 3, respectively. No case demonstrated TMPRSS2::ERG translocation. All cases were microsatellite stable and had lower tumor mutation burdens (range, 2.1-3.1 muts/Mb). The patients showed no biochemical recurrence or metastasis after follow-up of 16-91 months. Conclusions: iIDC-P is a special type of intraductal carcinoma of the prostate and differs from intraductal carcinoma within high-grade prostate cancer. iIDC-P has unique molecular characteristics and may represent as a molecularly unique in situ tumor of prostate cancer.

Distinctive Landscape of Genetic Mutation in Patients with Intraductal Carcinoma of the Prostate (IDC-P).

Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate

Cribiform and Intraductal Carcinoma in Hereditary Prostate Cancer: Clinical and Pathological Analysis of 20 Cases

Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate

Distinct Genomic Features and Evolutionary Relationships Between Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate.

The Presence and Clinical Implication of Intraductal Carcinoma of Prostate in Metastatic Castration Resistant Prostate Cancer.

Intraductal Carcinoma of the Prostate in Prostate Biopsy Samples: Correlation with Aggressive Pathological Features after Radical Prostatectomy and Prognostic Value in High-Risk Prostate Cancer

Supplementary Data from Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate

[Isolated intraductal carcinoma of the prostate: a clinicopathological and molecular analysis]

The Prognostic Implication of Intraductal Carcinoma of the Prostate in Metastatic Castration-Resistant Prostate Cancer and Its Potential Predictive Value in Those Treated with Docetaxel or Abiraterone As First-Line Therapy.

Is There Any Prognostic Impact of Intraductal Carcinoma of Prostate in Initial Diagnosed Aggressively Metastatic Prostate Cancer?

Germline Mutations in DNA Repair Genes in a Large Series of Unselected Chinese Prostate Cancer Patients.

Intraductal Carcinoma of the Prostate: What We Know and What We Do Not Know

The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy

Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives

Identification of recurrent BRAF non-V600 mutations in intraductal carcinoma of the prostate in Chinese populations

Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases Through 18 F-DCFPyL‒Prostate-Specific Membrane Antigen‒Positron Emission Tomography/CT Scans in Pretreatment Prostate Cancer Patients

The Heterogeneity of Intraductal Carcinoma of the Prostate is Associated with Different Efficacy of Standard First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer

Abstract 774: Detection of intraductal carcinoma of the prostate (IDCP) cases focusing on high-grade prostatic intraepithelial neoplasia (PIN) findings regarding invasive carcinoma of the prostate

Clinical transformation and basic research progress of intraductal carcinoma of the prostate

MDT perspective: intraductal carcinoma of the prostate: implication for diagnosis and treatment